April 21, 2021 -- GenScript ProBio is collaborating with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, on an antifibrosis antibody to treat idiopathic pulmonary fibrosis.
Both organizations will use next-generation technologies to accelerate the development of therapeutics. They will combine EDDC's high-throughput single B-cell cloning and recombinant antibody generation platform with GenScript ProBio's antibody drug discovery capacities including single B cell, phage display, hybridoma, fully human, and bispecific antibody technologies.
Financial details of the collaboration were not disclosed. GenScript ProBio is the contract development and manufacturing organization segment of GenScript Biotech.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
